KRAS and colorectal carcinoma: A recent study reveals that a chimeric receptor, CD16-158-valine on T cells, overcomes cetuximab resistance in KRAS mutant CRC, which indicates a new direction of CRC treatment, the combination of immune and molecule targets [46].